Nurix Therapeutics (NRIX) Stock Price, News & Analysis

Company Overview

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on harnessing the body’s natural protein regulation systems to discover and develop small-molecule therapeutics. The company leverages its proprietary targeted protein modulation (TPM) platform, including targeted protein degradation (TPD) and molecular glue approaches, to address unmet medical needs in oncology and immunology. Nurix’s pipeline includes multiple clinical-stage candidates designed to selectively degrade or modulate disease-causing proteins, offering a potential new class of precision medicines.

Among Nurix’s lead programs is NX-2127, a Bruton’s tyrosine kinase (BTK) degrader in clinical trials for B-cell malignancies, and NX-5948, a degrader targeting BTK and related kinases for immune-mediated diseases. These programs are underpinned by the company’s UbiLearn® research platform, which identifies novel E3 ligases, and the UbiFocus® lead optimization engine, which refines small molecules for enhanced efficacy and selectivity. Nurix also pursues earlier-stage discovery efforts in additional oncology targets, immuno-oncology combinations, and inflammatory disorders.

Nurix maintains strategic collaborations with leading pharmaceutical companies to expand the reach and application of its protein modulation technology. Notably, it has partnered with Gilead Sciences, Bristol-Myers Squibb, and Janssen Pharmaceuticals to co-develop degrader and molecular glue candidates across multiple therapeutic areas. These alliances provide Nurix with access to complementary expertise, resources and global development networks, accelerating the translation of its novel chemistry platforms into clinical assets.

Founded in 2015 and headquartered in San Francisco, California, Nurix Therapeutics is led by President and Chief Executive Officer Gary B. Evans, Ph.D., who brings extensive experience in drug discovery and biotechnology leadership. The company’s management team consists of seasoned professionals in research and development, regulatory strategy and commercialization. As Nurix advances its portfolio through clinical milestones and new partnerships, it aims to establish targeted protein modulation as a transformative approach for treating complex diseases worldwide.

Key Stats

• Today's Range: $12.37 to $12.90
• 50-Day Range: $9.30 to $13.18
• 52-Week Range: $8.18 to $29.56
• Volume: 1.41 million shs
• Average Volume: 850,512 shs
• Market Capitalization: $951.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $29.59
• Consensus Rating: Moderate Buy

Nurix Therapeutics Stock Analysis - MarketRank™

Nurix Therapeutics scored higher than 31% of companies evaluated by MarketBeat, and ranked 789th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 15 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Nurix Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Nurix Therapeutics are expected to decrease in the coming year, from ($2.99) to ($3.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nurix Therapeutics is -4.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nurix Therapeutics is -4.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nurix Therapeutics has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.93% of the float of Nurix Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Nurix Therapeutics has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Nurix Therapeutics has recently decreased by 2.56%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nurix Therapeutics does not currently pay a dividend.

Dividend Growth

Nurix Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

19.93% of the float of Nurix Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Nurix Therapeutics has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Nurix Therapeutics has recently decreased by 2.56%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.31

News Sentiment

Nurix Therapeutics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 23 news articles for Nurix Therapeutics this week, compared to 6 articles on an average week.

Search Interest

12 people have searched for NRIX on MarketBeat in the last 30 days. This is an increase of 140% compared to the previous 30 days.

MarketBeat Follows

3 people have added Nurix Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $137,096.00 in company stock.

Percentage Held by Insiders

Only 7.40% of the stock of Nurix Therapeutics is held by insiders.

NRIX Stock Analysis - Frequently Asked Questions

How have NRIX shares performed this year?

Nurix Therapeutics' stock was trading at $18.84 on January 1st, 2025. Since then, NRIX stock has decreased by 34.0% and is now trading at $12.44.

How were Nurix Therapeutics' earnings last quarter?

Nurix Therapeutics, Inc. (NASDAQ:NRIX) announced its quarterly earnings data on Wednesday, July, 9th. The company reported ($0.52) earnings per share for the quarter, beating analysts' consensus estimates of ($0.79) by $0.27. The firm earned $44,056 billion during the quarter, compared to analyst estimates of $16.26 million. Nurix Therapeutics had a negative net margin of 234.57% and a negative trailing twelve-month return on equity of 45.26%.

When did Nurix Therapeutics IPO?

Nurix Therapeutics (NRIX) raised $150 million in an initial public offering on Friday, July 24th 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel served as the underwriters for the IPO and Needham & Company was co-manager.

How do I buy shares of Nurix Therapeutics?

Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nurix Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nurix Therapeutics investors own include Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Advanced Micro Devices (AMD) and Visa (V).

Company Calendar

• Last Earnings: 7/09/2025
• Today: 7/13/2025
• Fiscal Year End: 11/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NRIX
• CIK: 1549595
• Web: www.nurixtx.com
• Phone: 415-660-5320
• Fax: N/A
• Employees: 300
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Nurix Therapeutics: $29.59
• High Price Target: $41.00
• Low Price Target: $16.00
• Potential Upside/Downside: +137.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$193.57 million
• Net Margins: -234.57%
• Pretax Margin: -233.61%
• Return on Equity: -45.26%
• Return on Assets: -34.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.82
• Quick Ratio: 6.26

Sales & Book Value

• Annual Sales: $54.55 million
• Price / Sales: 17.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.85 per share
• Price / Book: 2.13

Miscellaneous

• Outstanding Shares: 76,450,000
• Free Float: 70,792,000
• Market Cap: $951.04 million
• Optionable: Optionable
• Beta: 2.15